Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allarity Therapeutics, Inc. (NASDAQ: ALLR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Phase 2 clinical-stage biopharmaceutical company focused on stenoparib and its DRP® companion diagnostic platform, Allarity uses SEC reports to communicate material events, financing transactions, and periodic financial information to investors.
Among the key documents available are Form 8-K current reports, where Allarity has disclosed events such as FDA Fast Track designation for stenoparib in advanced ovarian cancer, new clinical data presentations from its Phase 2 ovarian cancer trial, conference participation on biomarkers and precision medicine, licensing and laboratory services agreements for DRP® algorithms, and private placement securities purchase agreements. Filings like NT 10-Q (Form 12b-25) explain timing of quarterly reports and provide context on the status of financial statement reviews.
Through Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of each document, helping users quickly understand disclosures related to clinical development, capital structure, registration rights, and governance changes. Real-time updates from EDGAR ensure that new Allarity filings are added as they become available, including quarterly and annual reports when filed, as well as any future Forms 10-K, 10-Q, or additional 8-Ks.
Investors researching ALLR can use this page to review how Allarity describes its business focus on stenoparib and DRP®, track unregistered equity offerings and registration rights agreements, and monitor other material events reported under SEC rules. The combination of original documents and AI-generated overviews is intended to make complex regulatory language more accessible while preserving the underlying source information.
Allarity Therapeutics, Inc. announced it has closed a $20 million non-convertible debt financing with Streeterville Capital, structured via two promissory notes of $10,930,000 and $10,000,000, providing approximately $20 million in net proceeds.
The company expects this financing to extend its cash runway into the summer of 2028 and primarily use the funds to advance stenoparib in advanced ovarian cancer, including completing its Phase 2 trial, preparing for an FDA End-of-Phase-2 meeting, and supporting pivotal development and commercialization plans, as well as further developing its DRP companion diagnostic platform.
Allarity Therapeutics, Inc. entered into a financing arrangement with Streeterville Capital through two new promissory notes. The company issued an A-1 Note with an original principal amount of $10,930,000 and a secured B Note with an original principal amount of $10,000,000, both maturing 18 months after issuance.
After closing, Streeterville paid $10,000,000 to Allarity, and another $10,000,000 was placed in a controlled deposit account owned by a new wholly owned subsidiary, ALLR Holdings, LLC. The A-1 Note has a 9.00% annual interest rate and includes a $900,000 original issue discount and $30,000 of expenses, while the B Note bears 5.00% annual interest.
Beginning six months after issuance, the lender may redeem up to $250,000 plus accrued interest per month, payable in cash. The notes are secured by the controlled account, a guaranty from the subsidiary, and a pledge of all membership interests in the subsidiary, and include covenants restricting additional variable-price or secured financings and certain subsidiary activities. Trigger and default events can increase the outstanding balance and raise the interest rate up to 15% per year.
Allarity Therapeutics, Inc. announced that the first patients have been dosed with stenoparib in combination with temozolomide in a U.S. Department of Veterans Affairs–funded investigator-initiated Phase 2 trial for relapsed small cell lung cancer, an area described as having high unmet medical need.
The trial is fully funded through the VA’s Special Emphasis Panel on Precision Oncology and is open for enrollment across 11 VA medical centers in the United States. Allarity highlights stenoparib’s dual PARP and WNT pathway inhibition, its favorable safety profile compared with earlier PARP inhibitors, and its ability to cross the blood-brain barrier as potential advantages in this setting.
Allarity Therapeutics is registering 255,103 shares of common stock for resale by a single selling stockholder. These shares were issued on December 23, 2025 as “Additional Shares” in a private placement at $0.98 per share, which previously generated approximately $250,000 in gross proceeds for the company.
The resale registration is purely for the stockholder’s benefit; Allarity will not receive any proceeds when these shares are sold. As context, 16,080,980 shares of common stock were outstanding as of February 11, 2026, and the Nasdaq closing price that day was $0.90 per share.
In earlier tranches of the private placement, Allarity sold 760,916 shares and 801,584 pre-funded warrants for roughly $2.5 million in gross proceeds and may sell up to $6.0 million of additional stock over time under a separate equity line agreement. The company remains a clinical-stage oncology business focused on stenoparib and operates as an emerging growth and smaller reporting company, highlighting ongoing capital needs and potential future dilution.
Allarity Therapeutics, Inc. reported that enrollment has opened for a new Phase 2 clinical trial. The study evaluates a combination of stenoparib and temozolomide to treat patients with recurrent small cell lung cancer.
The company released a press statement about this development, which is included as an exhibit to the report and incorporated by reference.
Allarity Therapeutics, Inc. has entered a common stock purchase agreement with Tumim Stone Capital that allows the company, at its discretion, to sell up to $6.0 million of common stock over 24 months. Under Nasdaq’s 19.99% exchange cap, this prospectus supplement registers 3,214,588 shares for resale by Tumim.
Sales prices will be based on a discount to volume-weighted average trading prices, so the actual number of shares issued will vary with the stock price. As of January 27, 2026, Allarity had 16,080,980 shares outstanding and a public float of approximately $20.1 million.
The company warns that issuing shares to Tumim and Tumim’s subsequent resales could significantly dilute existing stockholders and pressure the share price. Any proceeds Allarity receives from selling shares to Tumim are expected to be used for working capital and general corporate purposes, including potential debt repayment and operating expenses.
Allarity Therapeutics, Inc. entered into a Common Stock Purchase Agreement with Tumim Stone Capital, creating an equity line of credit that allows the company, at its sole discretion, to sell up to $6,000,000 of newly issued common shares over time.
Shares sold under the agreement will be priced at a discount to market, equal to either 95% of the lowest one-day volume‑weighted average price or 97% of the lowest three‑day volume‑weighted average price, subject to volume and dollar limits per draw of up to $1,000,000 or $2,000,000.
The investor cannot exceed 4.99% ownership of outstanding common stock, or 9.99% if it elects that higher cap. Issuances are also limited by an Exchange Cap tied to 19.99% of pre‑agreement shares outstanding, unless stockholders later approve a waiver and, if needed, an increase in authorized shares. Allarity paid a $45,000 commitment fee for this financing flexibility.
Allarity Therapeutics, Inc. reported an equity award to senior executive Jeremy R. Graff, its President and Chief Development Officer. On January 7, 2026, Graff received 133,333 shares of common stock in the form of restricted stock units at a price of $0 per share under the company’s Amended and Restated 2021 Equity Incentive Plan. These RSUs will vest in three equal one-third installments on the first, second, and third anniversaries of the grant date, conditioned on his continued relationship with the company. Following this award, Graff beneficially owns 381,644 shares of Allarity Therapeutics common stock, held directly.
Allarity Therapeutics (ALLR) filed its Q3 2025 report, highlighting a smaller quarterly net loss and stable liquidity. Net loss was $2.8 million for the quarter and $7.9 million year-to-date. Cash and cash equivalents were $16.9 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months.
Operating cash outflow was $11.6 million for the nine months. The company raised capital via an ATM program with $9.7 million net proceeds year-to-date and completed a private placement of 1,562,500 shares at $1.60 per share for roughly $2.5 million gross. Allarity also executed a share repurchase program, buying 2,600,763 shares for $2.706 million, with $2.294 million remaining authorized.
The FDA granted Fast Track designation to stenoparib for advanced ovarian cancer, supporting development interactions. The company reported a material weakness in internal controls related to accounting for the repurchase program and is implementing remediation. Shares outstanding were 16,111,461 as of September 30, 2025; 15,811,886 were reported outstanding as of November 13, 2025.
Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc. (ALLR), reported transactions dated 09/30/2025. 39,494 restricted stock units vested and were reported as acquired, and 14,613 shares were disposed of at $1.58 per share, leaving 24,881 shares owned directly after the transactions. The filing also shows 223,430 restricted stock units/derivative securities beneficially owned following the reported transactions. The RSUs convert one-for-one to common stock and stem from grants of 118,483 RSUs on 09/30/2024 and 144,441 RSUs on 01/22/2025, each vesting in three equal annual installments beginning on the first anniversary of the respective grant dates.